<DOC>
	<DOCNO>NCT00861120</DOCNO>
	<brief_summary>The purpose study investigate response rate platinum-resistant , KRAS wild-type , ovarian cancer patient treat pegylated liposomal doxorubicin ( Caelyx® ) combination biological treatment panitumumab ( Vectibix® ) .</brief_summary>
	<brief_title>Panitumumab Pegylated Liposomal Doxorubicin Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type</brief_title>
	<detailed_description>Patients platinum-resistant recurrent ovarian cancer therapeutic option response rate 10-20 % use non-cross-resistant chemotherapeutic agent . New biologic agent combination chemotherapy treatment modality may result improvement survival . Recent result colorectal cancer clearly indicate KRAS mutant tumor respond treatment EGFR inhibitor . Panitumumab ( ABX-EGF ) first fully human monoclonal antibody specific EGF receptor . To date , panitumumab evaluate combination chemotherapy patient CRC , NSCLC , SCCHN . No previous study evaluate effect panitumumab epithelial ovarian cancer base KRAS mutation status .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm epithelial primary ovarian , primary fallopian primary peritoneal cancer . Stage IIV . A : First line treatment platinum contain regimen either progression response 1.line chemotherapy , relapse within 6 month end 1. line chemotherapy , OR B : Patients receive second line platinum contain regimen either progression response second line chemotherapy , relapse within 6 month end second line chemotherapy Maximum two prior line chemotherapy ( platinumbased ) Age ≥ 18 year . Performance status 02 . Measurable disease CA125 GCIG criterion KRAS wild type Adequate bone marrow function , liver function , renal function coagulation parameter ( within 7 day prior randomization ) : WBC ≥ 3.0 x 109/l neutrophil ( ANC ) ≥ 1.5 x 109/l Platelet count ≥ 100 x 109/l Hemoglobin ≥ 9.7 g/dl ( 6 mmol/L ) Serum bilirubin ≤ 1.5 x UNL Serum transaminases ≤ 2.5 x UNL absence liver metastasis , ≤ 5xUNL presence liver metastases Serum creatinine ≤ 1.5 x UNL Magnesium ≥ low limit normal Calcium ≥ low limit normal Written inform consent Prior treatment chemotherapy biological target treatment except 1. line chemotherapy platinum combination platinum/taxane ( bevacizumab allow part 1. line treatment ) . Patients receive ( plan receive ) treatment investigational agent , participate another clinical trial within 28 day prior enter trial . Pregnant breastfeed plan become pregnant within 6 month end treatment . For fertile woman negative pregnancy test screen mandatory . Fertile patient willing use acceptable safe method contraception 6 month follow treatment Other present previous malignancy except curatively treated cervical cancer , nonmelanotic skin cancer cancer minimal risk relapse . CNS metastasis History chronic medical psychiatric condition laboratory abnormality medically control opinion Investigator may increase risk associated study drug administration . ( e.g . diabetes , cardiac disease , hypertension ) . Clinically significant cardiovascular disease ≤ 1 year enrollment/randomization , include : Myocardial infarction unstable angina within 6 month randomization . New York Heart Association ( NYHA ) ≥ Grade 2 congestive heart failure . Even medically control . Poorly control cardiac arrhythmia despite Medication ( patient ratecontrolled atrial fibrillation eligible ) Uncontrolled hypercalcemia ( calcium level outside upper limit normal ; antihypercalcemic treatment allow ) . Allergy ingredient study medication Staphylococcus Protein A History interstitial pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>KRAS wildtype</keyword>
	<keyword>Platinum resistant</keyword>
</DOC>